Salehi Samie, Saljooghi Amir Sh, Badiee Somayeh, Moqadam Mojtaba Mashmool
Department of Chemistry, Ferdowsi University of Mashhad, Faculty of Science, Mashhad 91775-1436, Iran.
Toxicol Res. 2017 Oct;33(4):299-304. doi: 10.5487/TR.2017.33.4.299. Epub 2015 Oct 15.
Thallium and its compounds are a class of highly toxic chemicals that cause wide-ranging symptoms such as gastrointestinal disturbances; polyneuritis; encephalopathy; tachycardia; skin eruptions; hepatic, renal, cardiac, and neurological toxicities; and have mutagenic and genotoxic effects. The present research aimed to evaluate the efficacy of the chelating agents deferasirox (DFX) and deferiprone (L1) in reducing serum and tissue thallium levels after the administration of thallium (III), according to two different dosing regimens, to several groups of Wistar rats for 60 days. It was hypothesized that the two chelators might be more efficient as a combined therapy than as monotherapies in removing thallium (III) from the rats' organs. The chelators were administered orally as either single or combined therapies for a period of 14 days. Serum and tissue thallium (III) and iron concentrations were determined by flame atomic absorption spectroscopy. Serum and tissue thallium (III) levels were significantly reduced by combined therapy with DFX and L1. Additionally, iron concentrations returned to normal levels and symptoms of toxicity decreased.
铊及其化合物是一类剧毒化学品，会引发多种症状，如胃肠功能紊乱、多发性神经炎、脑病、心动过速、皮肤疹、肝毒性、肾毒性、心脏毒性和神经毒性，并且具有致突变和基因毒性作用。本研究旨在根据两种不同给药方案，对几组Wistar大鼠连续60天给予铊（III）后，评估螯合剂地拉罗司（DFX）和去铁酮（L1）在降低血清和组织中铊水平方面的疗效。研究假设是，在从大鼠器官中清除铊（III）方面，这两种螯合剂联合治疗可能比单一治疗更有效。螯合剂作为单一或联合疗法口服给药14天。通过火焰原子吸收光谱法测定血清和组织中的铊（III）及铁浓度。DFX和L1联合治疗可显著降低血清和组织中的铊（III）水平。此外，铁浓度恢复到正常水平，毒性症状减轻。
